Generics Bulletin: ジェネリック&バイオシミラーニュース
Viatris And Biocon Line Up EU Bevacizumab
By David Wallace 26 Feb 2021
Viatris’ Mylan has received a positive opinion from the EMA’s CHMP for its bevacizumab biosimilar rival to Avastin under two...
Entries are now open for the Global Generics & Biosimilars Awards 2019, which will this year be presented on Tuesday 5 November at the Frankfurt Marriott Hotel in Frankfurt, Germany.
Now in their sixth year, the Awards – which are free to enter and attend – have added two new categories to the roster for 2019: Value Added Medicine Of The Year and Legal Strategy Of The Year.
Entries in the Value Added Medicine Of The Year category could include known molecules that are repurposed for new indications, reformulated in a way that adds value for patients, put together in innovative combinations, or which feature added-value packaging or delivery methods.
Meanwhile, the Legal Strategy Of The Year category allows generics, biosimilars and value-added medicines firms as well as their partnering law firms to highlight outstanding results from their legal strategy. This could include notable litigation results allowing a competitive advantage or early launch; inventive ways of getting around or invalidating intellectual property; or ways in which legal strategies from different global jurisdictions have been used as a template elsewhere, showing the benefits of a co-ordinated international legal strategy.
Companies and individuals involved in the generics, biosimilars and value added medicines industries can submit by 9 August 2019 their entries for all 14 awards, which will be judged by expert panels.
Awards available for entry include the Company of the Year Award as well as three local Company of the Year Awards for the Americas, EMEA and Asia-Pacific regions.
Other Awards include the Business Development of the Year Award – sponsored by West Pharma – as well as the Acquisition of the Year, API Supplier of the Year, Biosimilar Initiative of the Year, Regulatory Achievement of the Year and Industry Partner of the Year Awards.
Company leadership will be recognized by the Leader of the Year Award, while International Health Partners (IHP) will once again sponsor the Award for Corporate Social Responsibility (CSR) Initiative of the Year.
For more information an to enter the awards, please follow this link.
To book tables and to enquire about sponsorship opportunities, please e-mail rob.coulson@informa.com
To request tickets to attend the awards, and for any further details, please e-mail natalie.cornwell@informa.com
Generics Bulletin: ジェネリック&バイオシミラーニュース
By David Wallace 26 Feb 2021
Viatris’ Mylan has received a positive opinion from the EMA’s CHMP for its bevacizumab biosimilar rival to Avastin under two...
Generics Bulletin: ジェネリック&バイオシミラーニュース
By Dean Rudge 25 Feb 2021
Coherus BioSciences is aiming to translate the success of its comprehensive biosimilar pegfilgrastim strategy to adalimumab, with plans to capture...
Generics Bulletin: ジェネリック&バイオシミラーニュース
By David Wallace 23 Feb 2021
Medicines for Europe has called for fresh efforts to bolster the value added medicines sector and “level the playing field”...
専任スタッフによるデモンストレーションを兼ねたサービスの詳しいご説明、または無料トライアルを常時受け付けています。ご希望の場合は下記のフォームよりお気軽にお申し込みください。
*一部のサービスでは無料トライアルをご利用になれません。
新型コロナウイルス感染拡大防止のため在宅勤務を実施しています。お問合せの際は下記メールアドレスまたは各営業スタッフまでご連絡下さいますようご協力をお願い申し上げます。
インフォーマインテリジェンス合同会社
ファーマインテリジェンス
inquiry.jp@informa.com
*Omdia(ICT産業の情報)に関するお問い合わせはこちら
Contact_OmdiaJapan@omdia.com
オンラインショップのレポートストアでは、医療用医薬品の市場調査・分析レポートを常時1000本以上販売しています。レポート1本単位で購入でき、オンラインでご提供いたします。
お探しの情報が見つからない場合はお問い合わせ先までお気軽にご連絡ください。